Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis

• Published in: Molecular metabolism (Germany) Vol. 54; p. 101364
• Main Authors: Mukherjee, Sandip, Chakraborty, Molee, Ulmasov, Barbara, McCommis, Kyle, Zhang, Jinsong, Carpenter, Danielle, Msengi, Eliwaza Naomi, Haubner, Jake, Guo, Chun, Pike, Daniel P., Ghoshal, Sarbani, Ford, David A., Neuschwander-Tetri, Brent A., Chakraborty, Anutosh
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01-12-2021; Elsevier
• Subjects: Animals; Brief Communication; Choline Deficiency - metabolism; Dietary Sugars - adverse effects; Fatty Liver - metabolism; Hepatocytes - metabolism; Humans; Hyperglycemia; IP6K1; Liver; Metabolism; Mice; Mice, Inbred C57BL; NAFLD/NASH; Non-alcoholic Fatty Liver Disease - metabolism; O-GlcNAcylation; Phosphotransferases (Phosphate Group Acceptor) - deficiency; Phosphotransferases (Phosphate Group Acceptor) - genetics; Phosphotransferases (Phosphate Group Acceptor) - metabolism; O-GlcNAcylation; Hyperglycemia; IP6K1; NAFLD/NASH; Metabolism; Liver
• ISSN: 2212-8778; 2212-8778
• DOI: 10.1016/j.molmet.2021.101364

Obesity and insulin resistance greatly increase the risk of nonalcoholic fatty liver disease and steatohepatitis (NAFLD/NASH). We have previously discovered that whole-body and adipocyte-specific Ip6k1deletion protects mice from high-fat-diet-induced obesity and insulin resistance due to improved adipocyte thermogenesis and insulin signaling. Here, we aimed to determine the impact of hepatocyte-specific and whole-body Ip6k1 deletion (HKO and Ip6k1-KO or KO) on liver metabolism and NAFLD/NASH.
Body weight and composition; energy expenditure; glycemic profiles; and serum and liver metabolic, inflammatory, fibrotic and toxicity parameters were assessed in mice fed Western and high-fructose diet (HFrD) (WD: 40% kcal fat, 1.25% cholesterol, no added choline and HFrD: 60% kcal fructose). Mitochondrial oxidative capacity was evaluated in isolated hepatocytes. RNA-Seq was performed in liver samples. Livers from human NASH patients were analyzed by immunoblotting and mass spectrometry.
HKO mice displayed increased hepatocyte mitochondrial oxidative capacity and improved insulin sensitivity but were not resistant to body weight gain. Improved hepatocyte metabolism partially protected HKO mice from NAFLD/NASH. In contrast, enhanced whole-body metabolism and reduced body fat accumulation significantly protected whole-body Ip6k1-KO mice from NAFLD/NASH. Mitochondrial oxidative pathways were upregulated, whereas gluconeogenic and fibrogenic pathways were downregulated in Ip6k1-KO livers. Furthermore, IP6K1 was upregulated in human NASH livers and interacted with the enzyme O-GlcNAcase that reduces protein O-GlcNAcylation. Protein O-GlcNAcylation was found to be reduced in Ip6k1-KO and HKO mouse livers.
Pleiotropic actions of IP6K1 in the liver and other metabolic tissues mediate hepatic metabolic dysfunction and NAFLD/NASH, and thus IP6K1 deletion may be a potential treatment target for this disease.
[Display omitted]
•IP6K1 promotes NAFLD/NASH.•IP6K1 reduces mitochondrial oxidative capacity and increases insulin resistance in hepatocytes.•IP6K1 enhances protein O-GlcNAcylation in the liver.•Whole-body Ip6k1-KO mice are robustly protected from NAFLD/NASH whereas HKO mice display partial improvements.•IP6K1 is upregulated in the livers of human NASH and cirrhosis patients.